378 related articles for article (PubMed ID: 34678690)
21. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
[TBL] [Abstract][Full Text] [Related]
22. CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities.
Akhoundi M; Mohammadi M; Sahraei SS; Sheykhhasan M; Fayazi N
Cell Oncol (Dordr); 2021 Jun; 44(3):495-523. PubMed ID: 33759063
[TBL] [Abstract][Full Text] [Related]
23. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.
Rodriguez-Garcia A; Palazon A; Noguera-Ortega E; Powell DJ; Guedan S
Front Immunol; 2020; 11():1109. PubMed ID: 32625204
[TBL] [Abstract][Full Text] [Related]
24. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
25. CAR-T in solid tumors: Blazing a new trail through the brambles.
Guo F; Cui J
Life Sci; 2020 Nov; 260():118300. PubMed ID: 32827541
[TBL] [Abstract][Full Text] [Related]
26. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
28. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
29. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
30. CAR-T cell therapy in melanoma: A future success story?
Simon B; Uslu U
Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
[TBL] [Abstract][Full Text] [Related]
31. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V
J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
33. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors.
Tang XY; Ding YS; Zhou T; Wang X; Yang Y
Cancer Lett; 2021 Apr; 503():69-74. PubMed ID: 33476650
[TBL] [Abstract][Full Text] [Related]
34. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
35. Current Progress in CAR-T Cell Therapy for Solid Tumors.
Ma S; Li X; Wang X; Cheng L; Li Z; Zhang C; Ye Z; Qian Q
Int J Biol Sci; 2019; 15(12):2548-2560. PubMed ID: 31754328
[TBL] [Abstract][Full Text] [Related]
36. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.
Lundh S; Jung IY; Dimitri A; Vora A; Melenhorst JJ; Jadlowsky JK; Fraietta JA
Clin Exp Med; 2020 Nov; 20(4):469-480. PubMed ID: 32333215
[TBL] [Abstract][Full Text] [Related]
37. Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.
Fucà G; Reppel L; Landoni E; Savoldo B; Dotti G
Clin Cancer Res; 2020 Jun; 26(11):2444-2451. PubMed ID: 32015021
[TBL] [Abstract][Full Text] [Related]
38. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
39. Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.
Alcantara M; Du Rusquec P; Romano E
Oncoimmunology; 2020 Jun; 9(1):1777064. PubMed ID: 32934880
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of response and resistance to CAR T cell therapies.
Berger TR; Maus MV
Curr Opin Immunol; 2021 Apr; 69():56-64. PubMed ID: 33752101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
